Ex-The­seus ex­ecs ex­tend GIST mis­sion by tak­ing helm of IDRx

For­mer The­seus ex­ec­u­tives are now steer­ing the ship at Ben Aus­pitz and Alex­is Borisy’s IDRx as the biotech looks to con­tin­ue its mis­sion in the gas­troin­testi­nal stro­mal tu­mor (GIST) field, which has ex­pe­ri­enced lit­tle in­no­va­tion.

Tim Clack­son, the for­mer The­seus CEO and an R&D leader for more than 20 years at Ari­ad Phar­ma­ceu­ti­cals, will take Aus­pitz’s place in the chief ex­ec­u­tive post, the Boston-area biotech told End­points News. The­seus CFO Brad Dahms will step in­to the same post and tack on an ad­di­tion­al ti­tle of busi­ness chief.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER